Gross profit increased 338% to $3.6 million; operating loss narrowed to $0.7 million amid significant growth in Asia

Netanya, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, today announced its unaudited interim condensed consolidated financial results as of and for the six months ended June 30, 2026, together with a business update for the first half of 2026.

Nir Klein, Chief Executive Officer of Silynxcom, commented: “In the first half of 2026, we acted strategically and proactively to expand the presence and brand awareness of Silynxcom in new markets. We established strategic relationships with agents and resellers and significantly strengthened our global channel network.

“We believe we have laid a solid foundation in many countries across Asia and Europe and reinforced our existing relationships in additional markets worldwide. These efforts are already bearing fruit. Since the beginning of 2026, we have experienced impressive sales momentum from our customers and have also further strengthened our relationships with existing clients.

“We are fully committed to maintaining this strong momentum throughout 2026 and continuing to expand our global footprint while delivering greater value to our customers around the world.”

Key Highlights as of and for the Six Months Ended June 30, 2026:

  • Revenue for the six months ended June 30, 2026, amounted to $6.2 million, representing an increase of 174% compared to $2.3 million in the first half of 2025. The Company maintained a solid gross profit of $3.6 million, representing an increase of 338% compared to $0.8 million in the first half of 2025.
  • Cash and cash equivalents as of June 30, 2026, totaled $2.6 million.
  • Trade receivables, net, as of June 30, 2026, increased by 46% compared to December 31, 2025.
  • Positive shareholders’ equity: Preserved a healthy equity base of $5 million.
  • Significant growth in Asia: Revenue from Asia was $3.1 million in the six months ended June 30, 2026, compared with $0.1 million in the first half of 2025, driven by heightened demand for tactical communication systems.
  • Operating loss: narrowed to $0.7 million for the six months ended June 30, 2026, compared with an operating loss of $1.6 million for the six months ended June 30, 2025.

About Silynxcom Ltd.

For additional information about the Company please visit: https://silynxcom.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. For example, the Company uses forward-looking statements when it discusses  the Company’s expectations to maintain sales momentum throughout 2026, its plans to continue expanding its global footprint and its ability to deliver greater value to customers around the world. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on April 30, 2026, and other documents filed with or furnished to the SEC, which are available on the SEC’s website, www.sec.gov. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Capital Markets & IR Contact

ir@silynxcom.com

MONROE TOWNSHIP, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or the “Company”) (NYSE American: OPTT), a leader in maritime operational infrastructure and autonomous ocean systems, today announced leadership changes intended to strengthen execution, commercial conversion and operational accountability as the Company increases its focus on converting commercial opportunities into backlog and revenue.

The leadership transition is designed to build on the operational foundation established during fiscal 2026 and align the organization around its next phase of commercial execution, customer delivery and disciplined financial performance.

Effective September 14, 2026, Dr. Philipp Stratmann will step down from his roles as President and Chief Executive Officer and a member of the Board of Directors, by mutual agreement, and will remain available to assist the new leadership team through a transition period.

“As discussed in the Company’s fiscal 2026 results, OPT spent the past year establishing the operational foundation needed to support larger deployments and recurring revenue programs,” said Chairman Rear Admiral (retired) Joseph A. DiGuardo Jr. “With that foundation in place, the Board believes this is the appropriate time to transition leadership and sharpen the Company’s focus on execution, commercial conversion and operational accountability. Our priority now is disciplined execution—converting opportunities into contracts, contracts into revenue, and delivering successfully for our customers. The leadership structure announced today creates clear accountability around those objectives and positions OPT to execute on the opportunities in front of us.”

“Dr. Stratmann played an important role in OPT’s evolution from a technology-development company into an operating maritime technology business. Under his leadership, OPT expanded its maritime technology portfolio, strengthened its position in defense and security markets, expanded internationally and built many of the operational capabilities that support the Company today. On behalf of the Board, we thank Philipp for his dedication and significant contributions to OPT and wish him and his family the very best,” Chairman DiGuardo added.

Also, effective September 14, 2026, Tracy Pagliara, who previously served for six years as the Chief Executive Officer of a public company and is a Certified Public Accountant, will become Acting Chief Executive Officer and President and a member of the Board of Directors. Mr. Pagliara currently serves as the Company’s Senior Vice President, General Counsel and Secretary and brings both public-company leadership experience and deep knowledge of OPT’s business, operations and strategic priorities.

Jason Weed, currently Senior Vice President, Commercial Sales, has also been appointed as Chief Operating Officer, effective September 14, 2026, with responsibility for commercial sales, operations and technology and innovation, creating clear executive accountability from customer opportunity through execution and delivery. Mr. Weed has helped build OPT’s current pipeline and backlog and brings significant leadership experience from his service as a Captain in the U.S. Navy, including commanding the US Navy’s Unmanned Undersea Vehicle Squadron.

This leadership structure is intended to build on the platform established during fiscal 2026 and align the organization more directly around backlog conversion, customer delivery and disciplined execution. The new leadership structure creates clear accountability around the Company’s immediate priorities: converting pipeline opportunities into backlog and revenue, executing against existing customer commitments, maintaining disciplined financial management, and accelerating delivery of customer-driven solutions to market.

The Company remains focused on its existing maritime autonomy and Maritime Domain Awareness strategy and on translating its technology portfolio, customer relationships and commercial pipeline into sustainable revenue growth.

For more information about Ocean Power Technologies, visit www.OceanPowerTechnologies.com.

ABOUT OCEAN POWER TECHNOLOGIES

OPT provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets, including Merrows™, which provides AI capable seamless integration of Maritime Domain Awareness Systems across platforms. Our PowerBuoy® platforms provide clean and reliable electric power and real-time data communications for remote maritime and subsea applications. We also provide WAM-V® unmanned surface vessels (USVs) and marine robotics services. The Company’s headquarters is in Monroe Township, New Jersey, with an additional office in Richmond, California. To learn more about OPT’s products, services and solutions, visit www.OceanPowerTechnologies.com.

FORWARD-LOOKING STATEMENTS

This release may contain forward-looking statements that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates that could be inaccurate and subject to risks and uncertainties, including the Company’s ability to have a successful leadership transition, the delivery of customer services, the conversion of potential customers to contracts and the realization of the potential revenue thereunder. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the U.S. Securities and Exchange Commission for further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

Contact Information

Investors: 203-561-6945 or investorrelations@oceanpowertech.com

Media: 609-730-0400 x402 or MediaRelations@oceanpowertech.com

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6%

At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose

Publication expands peer-reviewed clinical evidence supporting Daré Bioscience’s proprietary topical Sildenafil Cream formulation

SAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced the publication of results from a Phase 1 clinical study evaluating the safety and systemic pharmacokinetics of topical Sildenafil Cream, 3.6% in healthy adult men in Sexual Medicine, an official journal of the International Society for Sexual Medicine. The article, titled, “An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults,” discusses findings from the study evaluating a higher and lower dose of topical Sildenafil Cream applied to the penis with and without condom use compared with a 50 mg oral dose of sildenafil. Access the full publication here.

“We are a women’s health company, and that remains at the center of everything we do. One of Daré Bioscience’s core strengths is our ability to apply sophisticated formulation and drug-delivery science to well-understood active ingredients in ways designed to address important gaps in care,” said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. “These peer-reviewed results are exciting because they demonstrate the potential power of that approach. Topical dosing is targeted and has been shown to result in substantially lower systemic exposure than an oral dose of sildenafil. This study in men provided additional clinical insight into our proprietary topical Sildenafil Cream formulation and expanded the evidence supporting its differentiated delivery profile. We believe that knowledge ultimately strengthens the scientific foundation of our work in women’s sexual health while also supporting the broader potential of Daré Bioscience’s formulation.”

The open-label, randomized study enrolled 62 healthy men who received a single dose of either 36 mg or 71 mg of sildenafil in topical cream, with or without condom use, or a 50 mg oral dose of sildenafil in tablet form. The study evaluated safety and systemic pharmacokinetics of sildenafil and its active metabolite, N-desmethyl sildenafil.

The study treatments were well tolerated, with all 14 treatment-emergent adverse events reported during the study characterized as mild. Seven of the 14 events occurred in five participants who received oral sildenafil. There were no serious adverse events, severe adverse events, deaths or discontinuations due to treatment-emergent adverse events.

Importantly, Daré Bioscience’s proprietary topical Sildenafil Cream resulted in substantially lower systemic exposure to sildenafil compared with the oral sildenafil group. Mean maximum plasma concentrations for sildenafil following topical administration (all four Sildenafil Cream dosing groups) ranged from 969 to 1,274 pg/mL, compared with 238,000 pg/mL for the oral sildenafil group. Relative bioavailability of sildenafil following topical administration (all four Sildenafil Cream dosing groups) ranged from 2.55% to 3.20%, suggesting a much lower systemic exposure as compared with the oral sildenafil group.

At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following the 50 mg oral dose, while systemic exposure measured by AUClast and AUCinf was approximately 33-fold and 34-fold lower, respectively. 71 mg sildenafil in 2 grams of cream was the dose tested in a subsequent Phase 2b study of Sildenafil Cream, 3.6% in premenopausal women for treatment of female sexual arousal disorder.

“These Phase 1 findings provide important clinical evidence regarding the potential safety and pharmacokinetic profile of topical Sildenafil Cream in men,” said David Friend, PhD, Chief Scientific Officer of Daré Bioscience. “The substantially lower systemic exposure observed with topical administration is consistent with the rationale for localized delivery of sildenafil and supports continued development of our investigational Sildenafil Cream, 3.6% as a potential differentiated approach for arousal concerns.”

The study was designed as a safety and pharmacokinetic evaluation in healthy men without erectile dysfunction and therefore did not assess efficacy or erectile response. The publication adds to the clinical evidence supporting continued development of Daré Bioscience’s proprietary Sildenafil Cream, 3.6% formulation, which has been evaluated in women with female sexual arousal disorder.

While Daré Bioscience remains solely focused on advancing solutions for women’s health, the Company believes that a broader body of clinical evidence around its proprietary formulations can provide valuable scientific insights that ultimately strengthen the foundation for its work in women’s sexual health. The Phase 1 study in men provided additional clinical evidence characterizing the behavior of the proprietary Sildenafil Cream, 3.6% formulation and Daré Bioscience’s localized drug-delivery approach using sildenafil, a well-characterized active pharmaceutical ingredient. Sildenafil Cream, 3.6% has been clinically evaluated in women with female sexual arousal disorder, the clinically analogous condition to erectile dysfunction in men.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING STATEMENTS

Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to, statements relating to: the significance of data from the Phase 1 clinical study in men for Daré Bioscience’s Sildenafil Cream, 3.6% program; the potential therapeutic benefits and safety profile of Sildenafil Cream, 3.6% in women and men; the market opportunity for Daré Bioscience’s products; and the potential impact of the products that Daré Bioscience brings to market for women.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Daré Bioscience’s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; potential suspension and delisting of Daré Bioscience’s common stock from the Nasdaq Capital Market; Daré Bioscience’s dependence on grants and other financial awards from governmental entities and a private foundation; Daré Bioscience’s reliance on Section 503B-registered outsourcing facilities and other third parties to bring DARE to PLAY Sildenafil Cream* and other solutions to market as compounded drugs or as consumer health products and facilitate access to such products and the risk that those third parties do not perform as expected; difficulties in establishing and sustaining relationships with third-party collaborators; the risk that the U.S. Food and Drug Administration (FDA) could stop permitting Section 503B-registered outsourcing facilities to compound the drug substances in the proprietary formulations Daré Bioscience intends to bring or brings to market or changes the conditions under which those drug substances may be used in compounding or the compounded products may be distributed; the ability of outsourcing facilities for Daré Bioscience’s compounded products to maintain their registration with the FDA under Section 503B; the timing of establishing, and ability to maintain, state-required licensure or registration to enable fulfillment of prescriptions for DARE to PLAY Sildenafil Cream and other solutions brought to market via the Section 503B pathway; Daré Bioscience’s inexperience, as a company, in and limited infrastructure for commercializing products; the degree of market demand and acceptance for the products Daré Bioscience brings to market; competitive product launches; greater than expected costs to bring compounded drug products to market and marketing costs; shifts in consumer spending or behavior; Daré Bioscience’s reliance on third parties to manufacture and conduct clinical trials and preclinical studies of its product candidates and commercialize XACIATO™ (clindamycin phosphate) vaginal gel 2% and future FDA-approved products, if any; the risk that the FDA’s 505(b)(2) pathway** for drug product approval in the U.S. is not available for a product candidate as Daré Bioscience anticipates; Daré Bioscience’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; Daré Bioscience’s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; decisions not to make clinical study design modifications recommended by the FDA; Daré Bioscience’s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the risks that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results for that study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré Bioscience’s interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that even if a pivotal clinical study achieves its primary efficacy endpoint, the FDA may determine the data package is not sufficient to support a favorable benefit-risk determination in a future marketing application; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré Bioscience anticipates, or that the duration of a study or number of study subjects must be significantly greater than anticipated; the loss of, or inability to attract, key personnel; product pricing and coverage and reimbursement from third-party payors; Daré Bioscience’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; Daré Bioscience’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; disputes or other developments concerning Daré Bioscience’s intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience’s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience’s products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; changes in healthcare, pharmaceutical, consumer protection or privacy laws and regulatory policies; increased scrutiny from regulators; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience’s ability to raise additional capital or on Daré Bioscience’s operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise Daré Bioscience’s technology systems and/or significantly disrupt Daré Bioscience’s business or those of third parties on which it relies.

Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

*The term DARE to PLAY describes a 503B compounded drug product. Compounded drug products are not approved by the FDA. The FDA does not evaluate compounded drug products for safety, effectiveness, or quality. References to Section 503B, 503B, 503B compounding, 503B compounded product, and similar terms refer to Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) and the production and supply of compounded drugs by Section 503B-registered outsourcing facilities without patient-specific prescriptions in accordance with Section 503B. Section 503B-registered outsourcing facilities are subject to FDA inspection and required to compound drug products under current Good Manufacturing Practice (cGMP) regulations to ensure quality, strength and consistency.

**The term FDA 505(b)(2) regulatory pathway refers to Section 505(b)(2) of the FDCA, which enables an applicant to rely, in part, on the FDA’s prior findings of safety and efficacy data for an existing product, or published literature, in support of the applicant’s new drug application (NDA), providing an alternate path to FDA approval for new or improved formulations or new uses of previously approved drugs.

Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.

Transaction in Own Shares

September 11, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 11 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency
11/09/2026 1,000,000 £ 35.7100 £ 35.1300 £ 35.4640 LSE GBP
11/09/2026 225,000 £ 35.7050 £ 35.1450 £ 35.4609 Chi-X (CXE) GBP
11/09/2026 – – – – BATS (BXE) GBP
11/09/2026 580,000 € 41.7150 € 41.0000 € 41.3999 XAMS EUR
11/09/2026 – – – – CBOE DXE EUR
11/09/2026 – – – – TQEX EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

World-first all-in-one energy storage system with Smart Port and Backup Port integration brings greater flexibility, resilience and intelligent energy management to South African homes

SANDTON, South Africa, Sept. 14, 2026 (GLOBE NEWSWIRE) — Sigenergy (06656.HK) today announced the South African launch of SigenStor Neo, its next-generation all-in-one residential energy storage system, at the Herholdt’s Group Summit 2026, held at The Galleria in Sandton.

The launch introduces Sigenergy’s latest residential energy innovation to the South African market, combining energy storage, power conversion, energy management and intelligent control within one integrated platform.

Sigenergy

At the centre of SigenStor Neo is its new Smart Port and Backup Port architecture. As the world’s first all-in-one energy storage system to integrate both a dedicated Smart Port and Backup Port, SigenStor Neo is designed to become the central hub of a broader home energy ecosystem.

For South African homeowners, this creates greater flexibility when building, upgrading or expanding a home energy system. The Smart Port can connect third-party inverters, external generators and EV chargers, allowing different energy assets to work within a more integrated system, while the Backup Port supports extended power supply to household loads during grid interruptions.

20260914-201748

“South Africa is an important market for Sigenergy, with customers increasingly looking for energy solutions that provide greater resilience, flexibility and control. SigenStor Neo represents the next evolution of our residential offering, combining advanced hardware with intelligent energy management in one integrated system. We are excited to officially introduce it to the South African market together with our partners at the Herholdt’s Group Summit.”
— Eon Geldenhuys, Senior Regional Solution & Service Manager – Africa at Sigenergy

The Core of a More Flexible Home Energy Ecosystem

SigenStor Neo builds on Sigenergy’s all-in-one approach by integrating the inverter, battery, power conversion system (PCS), energy management system (EMS) and gateway into a single streamlined system.

The addition of the Smart Port expands this concept beyond energy storage alone. It gives homeowners greater freedom to connect additional energy resources and devices as their requirements evolve.

For a homeowner with an existing inverter, for example, the Smart Port provides a pathway to integrate that equipment rather than treating the new storage system as an entirely separate installation. An external generator can also be incorporated into the wider home energy setup, while EV charging can form part of the same connected ecosystem.

This flexibility is particularly relevant for South African customers who may be upgrading an existing solar installation, adding storage to an established system or planning for future energy requirements.

Rather than designing the home around multiple independent energy devices, SigenStor Neo is designed to bring these elements together around a central energy platform.

Designed for Reliable Backup Power

Alongside its connectivity features, SigenStor Neo has been engineered to provide reliable household backup power.

The system delivers 0 ms load-side disruption and up to 200% peak power output capacity, helping household loads continue operating when grid power is interrupted.

The dedicated Backup Port further strengthens this capability by providing a flexible extended power supply for household loads during unexpected grid outages.

For South African households where backup capability remains an important consideration, these features provide a more integrated approach to managing the transition between grid power, stored energy and other available energy resources.

The Smart Port also enables an external generator to form part of the system, giving homeowners additional flexibility in how backup resources are configured and used.

Storage That Can Grow with the Home

SigenStor Neo has also been designed around modularity and long-term flexibility.

Its architecture supports up to six vertically stacked battery modules, allowing homeowners to configure storage capacity according to their current requirements and expand the system as their energy needs change.

This means customers can start with a system suited to their present electricity consumption rather than necessarily installing their maximum future storage requirement from the outset.

A built-in pack optimiser further supports future expansion by allowing compatible old and new batteries to operate within the same system. The system also incorporates an eight-layer protection architecture designed to enhance safety throughout operation.

For households whose energy requirements may change over time – whether through increased electricity consumption, additional solar capacity or future EV ownership – the modular approach provides a clear pathway for expansion.

Simpler Installation for Energy Professionals

The all-in-one architecture also delivers practical benefits for installers.

By integrating the inverter, battery, PCS, EMS and gateway within one system, SigenStor Neo reduces the need for multiple separate components and associated wiring.

The system uses lightweight modules with lifting handles, a single side cover for wiring, and an optimised terminal layout and installation process designed to reduce deployment time and on-site labour.

For installers, this can simplify deployment while also enabling a cleaner and more compact installation for the homeowner.

Bringing AI into Home Energy Management

SigenStor Neo forms part of Sigenergy’s wider “AI in All” strategy, through which artificial intelligence is integrated across the company’s energy ecosystem.

At the heart of the intelligent management layer is SigenAgent, Sigenergy’s all-domain AI energy agent operating through mySigen App 4.0.

Rather than requiring homeowners to manually manage every operating parameter, SigenAgent enables users to set broader objectives, such as reducing electricity costs or maintaining sufficient backup power. The system can then analyse conditions and automatically coordinate connected hardware in support of those objectives.

This combination of intelligent software and connected hardware allows SigenStor Neo to operate as more than a standalone storage system. It becomes part of a wider home energy ecosystem in which generation, storage, backup resources and connected devices can be managed together.

Introducing the Next Generation of SigenStor to South Africa

The launch of SigenStor Neo at the Herholdt’s Group Summit 2026 provides Sigenergy with an opportunity to introduce its latest residential energy technology directly to South Africa’s solar and energy industry.

The Summit brings together professionals across solar technology, artificial intelligence and business strategy, with Sigenergy participating through technology presentations and relevant project case studies.

Introducing SigenStor Neo at the event also reflects Sigenergy’s continued focus on working closely with local partners, installers and customers as new energy technologies are introduced to the South African market.

Sigenergy

With its combination of all-in-one design, world-first Smart Port and Backup Port integration, modular scalability, backup capability and AI-driven energy management, SigenStor Neo represents the next generation of Sigenergy’s residential energy storage offering in South Africa.

About Sigenergy

Founded in 2022 and headquartered in Shanghai, Sigenergy (06656.HK) is a technology-driven company focused on innovation in the new energy sector. Leveraging advanced digital intelligence and a highly skilled talent base, the company has expanded into photovoltaic (PV) generation, smart energy storage and high-efficiency electric vehicle (EV) charging.

Guided by its “AI in All” strategy, Sigenergy integrates artificial intelligence across its product ecosystem to deliver safer, smarter and more efficient energy solutions for households worldwide.

MEDIA ENQUIRIES Charl Ducray
charl@sigenergy.com
www.sigenergy.com
   

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/71be213d-cc04-4c14-8487-03ea1089ca53

https://www.globenewswire.com/NewsRoom/AttachmentNg/76ec8fb6-4604-4a9c-947a-50fc1d99e6b8

https://www.globenewswire.com/NewsRoom/AttachmentNg/abac2815-eb60-4adc-b971-b31554d42772

TUCSON, AZ, Sept. 14, 2026 (GLOBE NEWSWIRE) — Liberty Star Minerals (OTCQB: LBSR) (“Liberty Star” or the “Company”), a U.S. mineral exploration company focused on strategic and commercially important critical minerals in southeast Arizona, today announced that it has engaged Rick Perry, former Governor of Texas and former U.S. Secretary of Energy, to serve as an advisor to the Company’s Board of Directors on critical minerals strategy.

Governor Perry served fourteen years as Governor of Texas, the longest tenure of any governor in the state’s history and later served as the 14th U.S. Secretary of Energy. Throughout his career in public service, Governor Perry has been a consistent advocate for American energy independence and the responsible development of the nation’s natural resources.

Governor Perry’s appointment comes at a critical time for U.S. resource security. China currently controls the overwhelming majority of the world’s processing and refining capacity for rare earth elements and other critical minerals, refining an estimated 90 percent of global rare earths and holding a similarly dominant position in the processing of cobalt, graphite, and gallium. This concentration of supply has left the United States and its allies dependent on a single foreign source for materials essential to defense systems, electric vehicles, semiconductors, and renewable energy technologies.

Liberty Star, through its Hay Mountain Holdings, LLC subsidiary, controls approximately 45 square miles of mineral claims in the Tombstone Mining District of southeast Arizona, encompassing rare earths, critical minerals, copper, molybdenum, and gold targets. The Company believes this consolidated, district scale position is well suited to help rebuild a domestic critical minerals supply chain and reduce U.S. reliance on foreign sources.

“Governor Perry brings a level of energy policy and national security expertise that is rare in our industry,” said Pete O’Heeron, Chairman of Liberty Star Minerals. “China’s grip on the critical minerals supply chain is one of the most significant economic and national security challenges facing this country. Having a leader of Governor Perry’s caliber advising our Board sends a strong signal about what we are building in Arizona and how seriously we take our role in restoring U.S. mineral independence.”

“For too long, the United States has allowed a foreign adversary to control the materials that power our economy, our military, and our future,” said Rick Perry. “Companies like Liberty Star, with real assets in the ground here in America, are exactly what we need to reduce that dependence. I look forward to working with the Board to help advance a domestic supply of critical minerals.”

Liberty Star will provide further updates on Governor Perry’s role and the Company’s critical minerals strategy as they develop.

About Liberty Star Minerals

Liberty Star Minerals is a U.S. exploration company focused on strategic and commercially important critical minerals. The Company’s Hay Mountain Holdings LLC, which includes the Red Rock Canyon Gold Project, Earp Ridge Copper Project, and American Strategic Minerals, is located in southeast Arizona within a regionally significant porphyry copper gold molybdenum system. Liberty Star is actively pursuing joint venture partnerships to advance its projects and is committed to establishing U.S. mineral independence through domestic exploration and development.

Forward-Looking Statements

This release contains forward-looking statements as defined by the U.S. Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and factors beyond the Company’s control that could cause actual results to differ materially from those expressed or implied. Forward-looking statements may include projections, expectations, plans, and assumptions regarding exploration results, mineral resources, advisory relationships, and future operations. For a detailed discussion of risk factors, refer to the Company’s Annual Report on Form 10-K and other filings with the SEC. Regulation S-K 1300 Compliance: Liberty Star is classified as an “Exploration Stage Issuer” under Subpart 1300 of Regulation S-K. The Company currently has no mineral resources or mineral reserves to report under this regulation. U.S. investors are cautioned not to assume that any part of the Company’s mineralized properties will be converted into measured or proven reserves.

Contact: Liberty Star Minerals, Tucson, Arizona, www.libertystaruranium.com

Liberty Star Minerals | Liberty Star Uranium & Metals Corp.
LBSR: OTCQB
http://www.lbsr.us
Contact: Liberty Star Minerals
Tracy Myers, Investor Relations
520-425-1433 – info@lbsr.us 

– Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range –

– Topline Data Expected in November 2026 –

ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced the completion of patient enrollment in its ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain (“CINP”) trial. The Company anticipates topline data readout of the study in November 2026. Positive results from this study, if achieved, would represent a significant milestone for the Company, as well as for patients suffering from CINP, a condition for which there are no FDA approved treatments.

“Health care provider and CINP patient interest in participating in our HAL-CINP Phase 2b CINP trial was very high, which led us to recruit to the top of our projected target range,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. “Based on our encouraging interim analysis, we remain confident that Halneuron® treatment can demonstrate pain improvement when compared with placebo treated patients when Phase 2b topline data are reported this November.“

Halneuron® CINP Phase 2b Trial (“HAL-CINP”) Overview (NCT06848348)

HAL-CINP is a randomized, phase 2b clinical trial evaluating the efficacy and safety of Halneuron® compared with placebo in 239 patients with moderate to severe neuropathic pain caused by prior platinum and/or taxane-based chemotherapy. Participants receive 8 subcutaneous doses of Halneuron® or placebo over a 14-day period and are followed for a total of 28 days for safety and effectiveness. The primary endpoint for this study is the change from baseline to week four in the weekly average of daily 24-hour recall pain intensity scores. The study is being conducted at approximately 25 sites in the U.S. Secondary measures will assess Halneuron’s® treatment effects on sleep, fatigue, neuropathy symptoms and overall patient health.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV.

Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain CINP. SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.

The three presentations address distinct questions about Annamycin: where it concentrates in the body, how it kills cancer cells, and whether it can also enlist the immune system to do so. Together they inform the Company’s development of Annamycin in hard-to-treat cancers.

Title: “Antitumor activity of ANNAMYCIN, a highly effective lipophilic DNA-binding drug: Impact of its organotropism”
Author/Presenter: Waldemar Priebe, PhD, UT MD Anderson Cancer Center
Congress: XIII Congress of the Polish Medical Diaspora
Dates: September 9–12, 2026
Location: Wroclaw, Poland

Annamycin’s lipophilic structure drives it to concentrate in specific tissues rather than distribute uniformly. Dr. Priebe’s presentation examines how that distribution relates to the antitumor activity observed across preclinical models, and what it may mean for treating tumors in those tissues.

Title: “Organotropism-guided exploration of anticancer properties of Annamycin (naxtarubicin), a potent topoisomerase II targeting agent”
Author/Presenter: Waldemar Priebe, PhD, UT MD Anderson Cancer Center
Event: Invited Lecture at the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
Date: September 14, 2026
Location: Wroclaw, Poland

This invited lecture extends the same line of inquiry to mechanism, examining how Annamycin’s tissue distribution interacts with its inhibition of topoisomerase II, the enzyme target through which anthracyclines produce DNA damage in dividing cells.

Title: “Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity”
Author/Presenter: Angela T. Alistar, MD, Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center
Congress: AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development
Dates: September 25–28, 2026
Location: Hilton San Diego Bayfront, San Diego, California

The abstract for this presentation remains under embargo until publication. Moleculin expects to report on the findings when the abstract is published, as described below.

Abstracts selected for presentation at the AACR Conference on Pancreatic Cancer will be published as a supplement to the September 15, 2026 issue of Cancer Research on September 25, 2026, at 1:00 p.m. ET.

“Annamycin’s ability to concentrate in specific tissues is one of the properties that most distinguishes it from currently prescribed anthracyclines, and it is the through-line across these presentations,” said Walter Klemp, Chairman, President and Chief Executive Officer of Moleculin. “Having this work presented by leading investigators, and accepted at an AACR conference, reflects the breadth of scientific interest in Annamycin beyond our lead indication in AML.”

These presentations run alongside Moleculin’s lead clinical program, the ongoing MIRACLE trial evaluating AnnAraC in patients with relapsed or refractory acute myeloid leukemia (AML). MIRACLE remains the Company’s primary development focus and the basis of its near-term milestones.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population (the interim results presented are based on a small sample size (n=45), have not achieved statistical significance, and may not be predictive of results from the completed trial). Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Acquisition Adds 55 MW of Contracted Power Capacity, including 15 MW Energized at Closing, Expanding AIB’s Total Contracted Portfolio from 65 MW to 120 MW

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — AIB Data Centers Inc. (NYSE American: AIB) (“AIB” or the “Company”), a developer and operator of digital infrastructure focused on artificial intelligence (“AI”) and high-performance computing (“HPC”) workloads, today announced the completion of a strategic acquisition of two adjacent parcels totaling approximately 29.4 acres in Texas. The acquisition increases AIB’s total contracted power capacity from 65 megawatts (“MW”) to 120 MW.

The site comprises a 5.0-acre parcel with 15 MW of energized service and an existing building shell, together with an adjacent 24.4-acre parcel carrying 40 MW of contracted service under a new facilities extension agreement, with the additional capacity currently under development. With the additional capacity secured, AIB’s commercial focus remains on converting its portfolio into long-term AI and HPC customer contracts, and the Company is in active discussions with prospective tenants.

AIB funded the approximately $11.2 million closing payment from cash on hand, with the $6.0 million deferred balance secured by a standby letter of credit issued by JPMorgan Chase Bank, allowing the Company to complete the acquisition without shareholder dilution or third-party debt financing. AIB closed the quarter ended June 30, 2026 with a strengthened financial position, including $52.8 million in cash, $82.7 million in stockholders’ equity, and no traditional debt.

Access to energized power remains a principal constraint on the deployment of AI and HPC infrastructure. The 15 MW in service at closing, together with the existing building shell, is expected to shorten the timeline from acquisition to deployment, while the additional 40 MW under development provides a defined path to expand capacity on the same footprint. The site’s approximately 55 MW of planned aggregate capacity is below the 75 MW threshold ERCOT and the Public Utility Commission of Texas use to classify “Large Loads” under the state’s large-load interconnection framework, including the Batch Zero process, while remaining subject to applicable utility, interconnection and regulatory requirements.

“Power is the gating constraint in AI infrastructure, and energized capacity with existing infrastructure is increasingly scarce,” said Jerry Tang, Chief Executive Officer of AIB Data Centers. “This acquisition expands our contracted power portfolio while adding a strategically located, scalable asset to our development portfolio. We believe the combination of available power, existing infrastructure, and additional contracted capacity can meaningfully compress the timeline from land acquisition to customer deployment while creating a strong foundation for future AI and HPC projects.”

About AIB Data Centers

AIB Data Centers Inc. is a developer and operator of digital infrastructure focused on AI hosting and high-performance computing workloads. The Company’s platform combines access to reliable, scalable power resources with modular infrastructure deployment designed to accelerate the development of next-generation compute capacity.

For more information, visit https://www.aib.us/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development and energization of additional electrical capacity at the site in Texas, the anticipated timing of capacity deployment, the applicability and impact of utility and regulatory requirements, and the Company’s development pipeline and growth strategy. These statements are based on management’s current expectations and are subject to risks and uncertainties, including the timing and completion of utility construction and interconnection work, changes in applicable laws, regulations or utility requirements, the availability of capital, customer demand, and other factors described in the Company’s filings with the Securities and Exchange Commission. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Investor Relations

Chris Tyson
Executive Vice President
MZ Group – MZ North America
Phone: (949) 491-8235
AIB@mzgroup.us
www.mzgroup.us

PARIS and NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Pasqal (Nasdaq: PSQL), a global leader in neutral-atom quantum computing, today announced the date for the release of its financial results for the first half of 2026, covering the six months ended June 30, 2026, and its participation in upcoming investor conferences.

First Half 2026 Earnings Call

Pasqal will report its first half 2026 financial results before the open of U.S. financial markets on Thursday, September 24, 2026. Pasqal will host a conference call with the financial community that day at 8:00 a.m. Eastern Time to discuss the results. A live webcast and archived replay of the call will be available on Pasqal’s investor relations website. To access the conference call by phone, please dial 1-877-497-9071 (U.S. and Canada) or 1-201-689-8727 (international).

Upcoming Investor Conferences

Wasiq Bokhari, Chief Executive Officer, and Stéphane Rougeot, Chief Financial Officer, will participate in the following upcoming investor conferences:

  • Tuesday, October 13, 2026 – Jefferies European Disruptive Tech Conference in London.
  • Wednesday, October 21, 2026 – Goldman Sachs Disruptive Technology Symposium in Paris.

Investors interested in scheduling meetings with Pasqal should contact their respective conference representatives.

Contacts

Investors
investors@pasqal.com

Media
pr@pasqal.com

About Pasqal

Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network). 

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.